US FDA Finalizes Nonclinical Test Guidance Intended To Spur NDAs For Novel NRTs
Executive Summary
Final guidance tracks nearly word-for-word with draft document detailing the agency’s thinking on animal studies for novel NRTs the Center for Drug Evaluation and Research published in August 2018.
You may also be interested in...
With FDA Guidance Urging Innovation, Will Novel Smoking Cessation Products Surface In US?
CDER reiterates expectation for multiple trials to demonstrate efficacy for an IND different from approved products, such as route of administration, for smoking cessation or reduction in risk of relapse. Agency offers access to expedited approval pathways by showing significant improvement in efficacy or safety over existing therapies or addressing unmet medical need.
With FDA Guidance Urging Innovation, Will Novel Smoking Cessation Products Surface In US?
CDER reiterates expectation for multiple trials to demonstrate efficacy for an IND different from approved products, such as route of administration, for smoking cessation or reduction in risk of relapse. Agency offers access to expedited approval pathways by showing significant improvement in efficacy or safety over existing therapies or addressing unmet medical need.
Will Novel NRT Interest Heat Up In US With First Clearance For ENDS Under Tobacco Control Act?
Without mentioning NRT space, FDA’s acceptance of one vape device and two replacement nicotine cartridges as tobacco products might reignite interest in proposals for ENDS or other novel products to be approved for smoking cessation claims. To gain clearance as tobacco products, the ENDS were shown to provide a benefit similar to efficacies required for an NRT.